{
  "pmcid": "7892528",
  "sha256": "e1b583087b4e74cc77c6841b65980bb549b7d1b990f9f065cc6c87030e71dded",
  "timestamp_utc": "2025-11-10T00:07:47.629335+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.174012268008806,
    "reading_ease": 24.008857345077104,
    "word_count": 289
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of SGM-101 for Intraoperative Fluorescence Imaging in Colorectal Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This ascending dose, exploratory study was conducted in the Netherlands, involving 37 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "involving 37 patients with primary or recurrent CRC"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients received a single dose of SGM-101 (5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg) intravenously"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine the optimal imaging dose of SGM-101 for intraoperative fluorescence imaging of primary and recurrent CRC."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The highest mean intraoperative tumor-to-background ratio (TBR) of 1.9 (p = 0.019) was observed at the 10 mg dose"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From January 2016 to January 2019, 37 patients were included."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "37 patients were included"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The highest mean intraoperative tumor-to-background ratio (TBR) of 1.9 (p = 0.019) was observed at the 10 mg dose, which showed a sensitivity of 96%, specificity of 63%, and negative predictive value of 94%."
      },
      "Harms": {
        "score": 1,
        "evidence": "All doses up to 15 mg were well tolerated, with no adverse events directly related to SGM-101."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The study is registered under ClinicalTrials.gov identifier NCT02973672"
      },
      "Funding": {
        "score": 1,
        "evidence": "was funded by the Centre for Human Drug Research"
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}